Recent Quotes (30 days)

You have no recent quotes
chg | %

Novadaq Technologies Inc.  

(Public, TSE:NDQ)   Watch this stock  
Find more results for NDQ
9.96
-0.06 (-0.60%)
May 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 9.96 - 10.03
52 week 7.95 - 16.42
Open 10.03
Vol / Avg. 1,200.00/3,874.00
Mkt cap 603.42M
P/E     -
Div/yield     -
EPS -1.38
Shares 57.80M
Beta 0.60
Inst. own     -
Jul 25, 2017
Q2 2017 Novadaq Technologies Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 17, 2017
Novadaq Technologies Inc Annual Shareholders Meeting
May 3, 2017
Q1 2017 Novadaq Technologies Inc Earnings Call - Webcast
May 3, 2017
Q1 2017 Novadaq Technologies Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -66.94% -66.08%
Operating margin -65.83% -67.94%
EBITD margin - -57.85%
Return on average assets -41.94% -33.82%
Return on average equity -53.41% -41.51%
Employees 307 -
CDP Score - -

Address

5090 Explorer Dr Suite 202
MISSISSAUGA, ON L4W 4T9
Canada
+1-905-6293822 (Phone)
+1-905-6290282 (Fax)

Website links

Description

NOVADAQ Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company's SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The SPY Fluorescence Imaging platform can be used to develop imaging devices specifically designed to meet the needs of different surgeons and other healthcare providers and the specialty procedures they perform. SPY images enable physicians treating life-threatening illnesses, such as breast, head and neck, colon, complex hernias, diabetes and certain cardiovascular diseases.

Officers and directors

William A. MacKinnon Chairman of the Board
Age: 69
Rick Mangat Ph.D. President, Chief Executive Officer
Roger Deck Chief Financial Officer
Lori Swalm Vice President of Marketing
Derrick Guo General Counsel, Corporate Secretary
Anthony F. Griffiths Lead Independent Director
Age: 85
Lisa N. Colleran Director
Age: 54
Karen A. Licitra Director
Patrice E. Merrin Independent Director
Age: 67
Thomas G. Wellner Independent Director
Age: 51